Morgan Stanley initiated coverage of Mural Oncology with an Overweight rating and $13 price target. The company’s cash runway into Q4 of 2025, coupled with a material commercial opportunity for a “differentiated” IL-2 asset in platinum-resistant ovarian cancer , should resonate with investors as the post-spin-off narrative takes hold, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
- Mural Oncology reports Q4 EPS ($3.57) vs ($2.91) last year
- Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
- Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)